H.C. Wainwright Believes Karyopharm Therapeutics (NASDAQ: KPTI) Won’t Stop Here

By Austin Angelo

H.C. Wainwright analyst Edward White assigned a Buy rating to Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $30. The company’s shares opened today at $18.59, close to its 52-week high of $18.93.

According to TipRanks.com, White is a 5-star analyst with an average return of 25.9% and a 53.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Mirati Therapeutics, and Fate Therapeutics.

Currently, the analyst consensus on Karyopharm Therapeutics is Strong Buy and the average price target is $24.50, representing a 31.8% upside.

In a report issued on May 15, Canaccord Genuity also reiterated a Buy rating on the stock with a $24 price target.

See today’s analyst top recommended stocks >>

Based on Karyopharm Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $10 million and GAAP net loss of $38.46 million. In comparison, last year the company had a GAAP net loss of $29.92 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma.